ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

hydronidone

Also written as “Hydronidone capsules”, “Hydronidone” and “[¹⁴C]Hydronidone”.

Its studies are mostly in Liver Cirrhosis · Hepatitis B, Chronic · Renal Insufficiency, Chronic · Hepatitis B, led by 2 companies.

Drug pageHydronidone: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 9, 202115 company-led studies, 3 open or runningNext primary completion: Dec 1, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GNI Group143 open or runningphase 3since Oct 9, 2021Oct 9, 2019Dec 1, 2026phase 1 · NCT07262333
Shanghai Genomicsits history only10 open or runningphase 2since Jun 26, 2015Jun 26, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GNI Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 9, 2019First study: no phase study in HealthyFirst studyNCT04125056 · 40 enrolled · China
  2. Oct 10, 2019Phase 1 study in Hepatitis BNCT04123769 · 8 enrolled · China
  3. Nov 12, 2019Phase 1 study in Pharmacokinetics of HydronidoneNCT04162821 · 48 enrolled · China
  4. Oct 9, 2021Phase 3 study in Liver CirrhosisNCT05115942 · 248 enrolled · China
  5. Jun 7, 2023Phase 3 study in Liver CirrhosisNCT05905172 · 248 planned · China
  6. Nov 17, 20253 phase 1 studiesNCT07262346, NCT07262333, NCT07263152
  7. Jan 7, 20262 phase 3 studiesNCT07343778, NCT07412236
  8. Jan 16, 2026Phase 2 study in Chronic Hepatitis B With Hepatic FibrosisNCT07364448 · 411 enrolled · China
  9. Jan 30, 2026Phase 1 study in Liver CirrhosisNCT07394309 · 30 enrolled · China
  10. Feb 11, 2026Phase 2 study in Chronic Hepatitis B-related Liver FibrosisNCT07417553 · 67 enrolled · China
  11. Mar 10, 2026Phase 1 study in Chronic Hepatitis B-related Liver FibrosisNCT07471217 · 6 enrolled · China

Ahead

  1. Dec 1, 2026Primary completion: phase 1 study in Renal Insufficiency, ChronicNCT07262333
  2. Jun 20, 2028Primary completion: phase 3 study in Liver CirrhosisNCT05905172
  3. Dec 30, 2028Primary completion: phase 3 study in Liver CirrhosisNCT07412236

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 GNI Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07471217Chronic Hepatitis B-related Liver Fibrosis · China1CompletedMay 6, 20266
NCT07417553Chronic Hepatitis B-related Liver Fibrosis · China2CompletedJul 27, 202667
NCT07394309Liver Cirrhosis · China1CompletedMay 11, 202630
NCT07412236Liver Cirrhosis · China3Not yet recruitingDec 30, 20281,208
NCT07364448Chronic Hepatitis B With Hepatic Fibrosis · China2CompletedJun 22, 2026411
NCT07343778Chronic Hepatitis B With Hepatic Fibrosis · China3CompletedJul 28, 2026337
NCT07263152Liver Cirrhosis · China1CompletedFeb 9, 202648
NCT07262346Liver Cirrhosis · China1CompletedMay 28, 2026138
NCT07262333Renal Insufficiency, Chronic · China1RecruitingDec 1, 202656
NCT05905172Liver Cirrhosis · China3RecruitingJun 20, 2028248
NCT05115942Liver Cirrhosis · China3CompletedOct 22, 2024248
NCT04162821Pharmacokinetics of Hydronidone · China1CompletedNov 27, 201948
NCT04123769Hepatitis B · China1CompletedOct 9, 20208
NCT04125056Healthy · China–CompletedJan 23, 201940

How it is read

Names in the registry

  • “Hydronidone capsules”, 7 entries
  • “Hydronidone”, 4 entries
  • “[¹⁴C]Hydronidone”, 1 entry
  • “Hydronidone Capsules”, 1 entry
  • “Hydronidone (270mg)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.